Approaches to vaccine prophilaxis of respiratory infections in patients with diabetes mellitus in the modern epidemiological situation
https://doi.org/10.14341/DM9820
Abstract
This review highlights the problems of vaccine prophylaxis of pneumococcal infection and influenza in patients with type 1 and type 2 diabetes mellitus (CD1 and CD2). The features of pneumococcal infection and influenza in conditions of unsatisfactory compensation of the disease are described. The necessity of protection against pneumococcal infection and influenza in the modern epidemiological situation is justified. Results of efficacy and safety of vaccination, including those in children with type 1 diabetes mellitus, are established. The existing foreign and domestic regulatory documents on vaccine prevention of actual infections are shown.Despite the available documents on vaccination of patients with diabetes, there are problems with inadequate immunization coverage of patients with CD1 and CD2 due to the lack of precise clinical recommendations for the management of these categories both inpatient and outpatient as these recommendations do not cover the questions of vaccine prophylaxis. In Russian studies only the treatment regimens are evaluated without taking into account the fact that vaccines are related to medicines and that the prevention of respiratory infections is a curative measure and can inhibit the development of complications of diabetes.It is necessary to coordinate the work of general practitioners, pediatricians, therapists and the efforts of endocrinologists to increase the coverage of immunization of patients with various forms of diabetes mellitus.
About the Authors
Alla A. Tarasova
Privolzhsky Research Medical University
Russian Federation
Russian Federation
MD, PhD
Michail P. Kostinov
I.I. Mechnikov Research Institute of Vaccines and Sera; Sechenov First Moscow State Medical Univesity
Russian Federation
Russian Federation
Julia A. Paramonova
City clinical hospital №38
Russian Federation
Russian Federation
References
1. International Diabetes Federation. Diabetes Atlas, 8th edition. IDF; 2017. 150 р. Available from: https://diabetesatlas.org/resources/2017-atlas.html.
2. Dedov I, Shestakova M, Benedetti MM, et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90−95. doi: https://doi.org/10.1016/j.diabres.2016.02.010
3. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., и др. Фармакоэпидемиологические аспекты мониторинга здоровья пациентов сахарным диабетом 2 типа: результаты российского наблюдательного многоцентрового наблюдательного исследования ФОРСАЙТ-СД2 // Сахарный диабет. — 2016. — Т. 19. — №6. — С. 443–456. [Dedov II, Kalashnikova MF, Belousov DYu, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus. 2016;19(6):443–456. (In Russ.)] doi: https://doi.org/10.14341/DM8146
4. Чучалин А.Г., Аметов А.С., Костинов М.П., и др. Современные подходы к вакцинопрофилактике пневмококковой инфекции у взрослых пациентов групп риска // Эндокринология: новости, мнения, обучение. — 2013. — №1. — С. 85–88. [Chuchalin AG, Ametov AS, Kostinov MP, et al. Modern approaches to vaccinal prevention of a pneumococcal infection at adults and patients of a risk groups. Endocrinology: news, opinions, training. 2013;(1):85–88. (In Russ.)]
5. Ежлова Е.Б., Мельникова А.А., Баранов А.А., и др. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Streptococcus pneumoniae. Методические рекомендации // Вакцинация. 2011. — Т. 1. — №2. — С. 36. [Ezhlova EB, Melnikova AA, Baranov AA, et al. Vaccine epidemiology and infection caused by Streptococcus Pneumoniae. Methodological recommendation. Vaccination. 2011;1(2):36. (In Russ.)]
6. Костинов М.П., Магаршак О.О., Полищук В.Б., и др. Вакцинация взрослых с бронхолегочной патологией. Руководство для врачей. — М.: Арт-студия «Созвездие», 2013. — 109 с. [Kostinov MP, Magarshak OO, Polishchuk VB, et al. Vaccination of adults with bronchopulmonary pathology. A guide for physicians. Moscow: Art-Studio «Sozvezdie»; 2013. 109 р. (In Russ.)]
7. Черданцев А.П., Костинов М.П., Кусельман А.И. Вакцинация беременных против гриппа и других инфекционных заболеваний. Руководство для врачей. 3-е изд., дополн. М.: МДВ, 2018. — 143 с. [Cherdantsev AP, Kostinov MP, Kuselman AI. Vaccination of pregnant women against influenza and other infectious diseases. A guide for doctors. 3th ed. Updated. Moscow: MDV; 2018. 143 р. (In Russ.)]
8. Shashank RJ, Samika SJ, Siddharth NS. Pneumococcal Vaccine in Diabetes: Relevance in India. J Assoc Physicians India. 2015;63(4 Suppl):34–35.
9. Kornum JB, Thomsen RW, Riis A, еt al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541–1545. doi: https://doi.org/10.2337/dc08-0138
10. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Hum Vaccin Immunother. 2016;12(11):2953−2958. doi: https://doi.org/10.1080/21645515.2016.1210744
11. Чучалин А.Г., Синопальников А.И., Козлов Р.С., и др. Российское респираторное общество (РРО). Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии (МАКМАХ). Клинические рекомендации по диагностике, лечению профилактике тяжелой внебольничной пневмонии у взрослых // Пульмонология. — 2014. — №4. — С. 13−48. [Chuchalin AG, Sinopal’nikov AI, Kozlov RS, et al. Russian Respiratory Society Interregional association on clinical microbiology and antimicrobial chemotherapy Clinical guidelines on diagnosis, treatment and prevention of severe community acquired pneumonia in adults. Pul’monologiya. 2014;(4):13−48. (In Russ.)]
12. Martins M, Boavida JM, Raposo JF, et al. Diabetes hinders community-acquired pneumonia outcomes in hospitalized patients. BMJ Open Diabetes Res Care. 2016;4(1):e000181. doi: 10.1136/bmjdrc-2015-000181
13. Yende S, van der Poll T, Lee M, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010;65(10):870−877. doi: 10.1136/thx.2010.136317.
14. Березняков И.Г., Махаринская Е.С., Дорошенко О.В. Особенности течения внебольничной пневмонии у пациентов с сахарным диабетом 2 типа // Журнал клинических и экспериментальных медицинских исследований. — 2013. — Т. 1. — №2. — С. 112−120. [Bereznyakov IG, Makharynskа OS, Doroshenko OV. Features of community-acquired pneumonia course in the patients with type II diabetes. Zhurnal klinicheskikh i eksperimental’nykh meditsinskikh issledovaniy. 2013;1(2):112−120. (In russ.)]
15. Брико Н.И., Намазова-Баранова Л.С., Костинов М.П., и др. Эпидемиология, клиника и профилактика пневмококковой инфекции. Учебное пособие для врачей. — М., 2017. — 112 с. [Briko NI, Namazova-Baranova LS, Kostinov MP, et al. Epidemiologiya, klinika i profilaktika pnevmokokkovoy infektsii. Uchebnoye posobiye dlya vrachey. Moscow; 2017. 112 p. (In Russ.)]
16. Федеральное руководство по использованию лекарственных средств (формулярная система, справочное издание). Вып. XVII / Под ред. А.Г. Чучалина, В.В. Яснецова. Глава 19 «Вакцины». — М.: ООО «Видокс», 2016. — С. 745−768. [Federal guidance on the use of drugs (formulary system reference book). Issue XVII. Ed. by A.G. Сhuchalin, V. V.Vasnecov. Chapter 19 «Vaccines». Moscow: OOO «Vidoks»; 2016. рр. 745−768. (In Russ.)]
17. Isturiz RE, Schmoele-Thoma B, Scott DA, et al. Pneumococcal conjugate vaccine use in adults. Expert Rev Vaccines. 2016;15(3):279−293. doi: https://doi.org/10.1586/14760584.2016.1132171
18. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31(35):3577−3584. doi: https://doi.org/10.1016/j.vaccine.2013.04.085
19. Webber C, Patton M, Patterson S, et al. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017;35(9):1266−1272. doi: https://doi.org/10.1016/j.vaccine.2017.01.032
20. McDonald HI, Thomas SL, Millett ER, et al. Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health records. BMJ Open Diabetes Res Care. 2017;5:e000332. doi: https://doi.org/10.1136/bmjdrc-2016-000332
21. Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198−2206. doi: https://doi.org/10.1080/21645515.2015.1030550
22. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114−1125. doi: https://doi.org/10.1056/NEJMoa1408544
23. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444−4449. doi: https://doi.org/10.1016/j.vaccine.2017.01.071
24. Principi N, Iughetti L, Cappa M. Streptococcus pneumoniae oropharyngeal colonization in school-age children and adolescents with type 1 diabetes mellitus: Impact of the heptavalent pneumococcal conjugate vaccine. Hum Vaccin Immunother. 2016;12(2):293−300. doi: https://doi.org/10.1080/21645515.2015.1072666
25. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. — М.: МДВ, 2009. — 252 с. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoy infektsii i grippa pri autoimmunnykh zabolevaniyakh. Rukovodstvo dlya vrachey. Moscow: MDV; 2009. 252 р. (In Russ.)]
26. Аксенова В.А., и др. Вакцины и вакцинация. Национальное руководство. Краткое издание / Под ред. В.В. Зверева, Р.М. Хаитова. — М.: ГЭОТАР-Медиа, 2014. — 636 с. [Aksenova V.A., et al. Vaktsiny i vaktsinatsiya. Natsional’noye rukovodstvo. Kratkoye izdaniye. Ed. by V.V. Zverev, R.M. Haitova. Moscow: GEOTAR-Media; 2014. 636 р. (In Russ.)]
27. Костинов М.П. Вакцинация детей с нарушенным состоянием здоровья: практическое руководство для врачей. 4-е изд. — М.: Медицина для всех, 2013. — 432 с. [Kostinov MP. Vaktsinatsiya detey s narushennym sostoyaniyem zdorov’ya: prakticheskoye rukovodstvo dlya vrachey. 4th ed. Moscow: Meditsina dlya vsekh; 2013. 432 р. (In Russ.)]
28. Костинов М.П., Скочилова Т.В., Тарасова А.А., и др. Уровень антител к пневмококковой вакцине у детей и подростков с сахарным диабетом 1-го типа // Проблемы эндокринологии. — 2009. — Т. 55. — №3. — С. 17−21. [Kostinov MP, Skochilova TV, Tarasova AA, et al. The level of antibodies to pneumococcal vaccine in children and adolescents with type 1 diabetes. Probl Endokrinol. 2009;55(3):17−21. (In Russ.)] doi: https://doi.org/10.14341/probl200955317-20.
29. Костинов М.П., Скочилова Т.В., Воробьева В.А., и др. Аутоантитела у детей и подростков с сахарным диабетом 1 типа после вакцинации против пневмококковой и гриппозной инфекций // Журнал микробиологии эпидемиологии и иммунобиологии. — 2009. — №2. — С. 53−57. [Kostinov MP, Skochilova TV, Vorobyeva VA, et al. Autoantibodies after vaccination against pneumococcal and influenaza infections in children and adolescents with type 1 diabetes mellitus. Journal of microbiology, epidemiology, and immunobiology. 2009;(2):53−57. (In Russ.)]
30. Зверев В.В., Костинов М.П., Магаршак О.О., и др. Руководство по клинической иммунологии в респираторной медицине. 2-е изд., дополн. — М.: МДB, 2018. — 304 с. [Zverev VV, Kostinov MP, Magarshak ОO, et al. Rukovodstvo po klinicheskoy immunologii v respiratornoy meditsine. 2nd, updated. Moscow: MDV; 2018. 304 р. (In Russ.)]
31. Респираторная медицина: руководство в 3 т. 2-е изд. перераб. и доп. / Под ред. А.Г. Чучалина. — М.: Литтерра, 2017. — Т. 2. — С. 173–183. [Respiratornaya meditsina: rukovodstvo v 3 t. Ed. by A.G. Chuchalin. 2nd revised and updated. Moscow: Litterra; 2017. Vol. 2. рр. 173−183. (In Russ.)]
32. Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015;16(12):1017−1029. doi: https://doi.org/10.1111/obr.12320
33. Grohskopf LA, Sokolowl Z, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendation of the Advisory Committee on Immunization Practices — United States, 2017-18 Influenza season. MMWR Recomm Rep. 2017;66(2):1−20. doi: https://doi.org/10.15585/mmwr.rr6602a1
34. American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes Care. 2015;38 Suppl:S41−48. doi: https://doi.org/10.2337/dc15-S010
35. Healthy People. Immunization and infectious diseases [cited 2015 Oct 21]. Available from: http://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases.
36. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013;12(5):519−536. doi: https://doi.org/10.1586/erv.13.35
37. Frasca D, Diaz A, Romero M, Blomberg BB. The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine. 2016;34(25):2834−2840. doi: 10.1016/j.vaccine.2016.04.023
38. McElhaney JE, Garneau H, Camous X, et al. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000140. doi: https://doi.org/10.1136/bmjdrc-2015-000140
39. Sheridan PA, Paich HA, Handy J, et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine. 2015;33(29):3306−3313. doi: https://doi.org/10.1016/j.vaccine.2015.05.043
40. Wang IK, Lin CL, Chang YC. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine. 2013;31(4):718−724. doi: https://doi.org/10.1016/j.vaccine.2012.11.017
41. Heymann AD, Shapiro Y, Chodick G, et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care. 2004;27(11):2581−2584. doi: https://doi.org/10.2337/diacare.27.11.2581.
42. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015;13:53. doi: https://doi.org/10.1186/s12916-015-0295-6
43. Alcusky MJ, Pawasauskas J. Adherence to guidelines for hepatitis B, pneumococcal and influenza vaccination in patients with diabetes. Clin Diabetes. 2015;33(3):116−122. doi: https://doi.org/10.2337/diaclin.33.3.116
44. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Hum Vaccin Immunother. 2016;12(11):2953−2958. doi: 10.1080/21645515.2016.1210744.
45. Тарасова А.А., Лукушкина Е.Ф., Колбасина Е.В., и др. Вакцинация против гриппа пациентов с сахарным диабетом 1-го типа // Актуальная инфектология. — 2015. — №1. — С. 74–77. [Tarasova AA, Lukushkina ЕF, Kolbasina ЕV, et al. Influenza vaccination in patients with diabetes mellitus type 1. Actual infectology. 2015;(1):74−77. (In Russ.)]
46. Алгоритмы специализированной медицинской помощи больным сахарным диабетом под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. — 2015. — Т.18. — №1S. — С. 1−112. [Standards of specialized diabetes care. Ed. by Dedov I.I., Shestakova M.V. (7th edition). Diabetes Mellitus. 2015;18(1S):1−112. (In Russ.)] doi: https://doi.org/10.14341/DM20151S1-112
47. Костинов М.П., Лавров В.Ф. Вакцины нового поколения в профилактике инфекционных заболеваний. Изд. 2-е, дополн. — М.: МДВ, 2010. — 192 с. [Kostinov MP, Lavrov VF. Vaktsiny novogo pokoleniya v profilaktike infektsionnykh zabolevaniy. 2nd ed. updated. Moscow: MDV; 2010. 192 р. (In Russ.)]
48. Рудакова А.В., Баранов А.А., Лобзин Ю.В., и др. Фармакоэкономические аспекты вакцинации детей 13-валентной пневмококковой конъюгированной вакциной в Российской Федерации // Вопросы современной педиатрии. — 2014. — Т.13. — №1. — С. 51−59. [Rudakova AV, Baranov AA, Lobzin YuV, et al. Pharmacoeconomic assessment of 13-valent pneumococcal conjugate vaccine in immunization of children in Russian Federation. Current Pediatrics. 2014;13(1):51–59. (In Russ.)] doi: 10.15690/vsp.v13i1.911
49. Зверев В.В., и др. Вакцинация против гепатита В, гриппа и краснухи взрослых пациентов с хроническими заболеваниями / Под ред. М.П. Костинова, В.В. Зверева. — М.: МДВ, 2009. — 196 с. [Zverev VV, et al. Vaktsinatsiya protiv gepatita V, grippa i krasnukhi vzroslykh patsiyentov s khronicheskimi zabolevaniyami. Ed. by M.P. Kostinov, V.V. Zverev. Moscow: MDV, 2009. 196 р. (In Russ.)]
50. Лиходей Н.В., Калашникова М.Ф., Лиходей Е.М., Фадеев В.В. Анализ факторов, препятствующих формированию приверженности лечению среди больных сахарным диабетом, и стратегий, способствующих ее повышению // Сахарный диабет. — 2018. — Т.21. — №1. — С. 5−14. [Likhodey NV, Kalashnikova MF, Likhodey EM, Fadeyev VV. Analysis of the factors that prevent adherence to treatment in patients with diabetes mellitus and the strategies that contribute to the improvement in adherence. Diabetes Mellitus. 2018;21(1):5−14. (In Russ.)] doi: https://doi.org/10.14341/DM8781
51. Bundesmann R, Kaplowitz SA. Provider communication and patient participitation in diabetes sef-care. Patient Educ Couns. 2011;85(2):143−147. doi: https://doi.org/10.1016/j.pec.2010.09.025.
52. Kimmel SR, Burns IT, Wolfe RM, Zimmerman RK. Adressing immunization barriers, benefits, and risks. J Fam Pract. 2007;56(2 Suppl Vaccines):S61−69.
53. Mirza A, Subedar A, Fowler SL, et al. Influenza vaccine: awareness and barriers to immunization in families of children with chronic medical conditions other than asthma. South Med J. 2008;101(11):1101−1105. doi: https://doi.org/10.1097/SMJ.0b013e318182ee8d.
54. Дедов И.И., Брико Н.И., Андрианова Е.П., и др. Обеспечение эпидемиологической безопасности при оказании помощи пациентам с сахарным диабетом: федеральные клинические рекомендации. Проект // Проблемы эндокринологии. — 2016. — Т.62. — №3. — С. 33−60. [Dedov II, Briko NI, Andrianova EA, et al. Assuring epidemiological safety for healthcare of patients with diabetes mellitus. Probl Endokrinol. 2016;62(3):33−60. (In Russ.)] doi: https://doi.org/10.14341/probl201662333-60.
55. Public Health England. Chapter 19: Influenza [cited 2014 March 20]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/796886/GreenBook_Chapter_19_Influenza_April_2019.pdf.
56. Robert Koch Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut [Internet]. Epidemiologisches Bulletin. 2013;34. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/34_13.pdf?__blob=publicationFile.
57. Canada Communicable Disease Report. NACI statement: Seasonal influenza vaccine, 2013–2014. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) [Internet]. CCDR; 2013. Vol. 39. ACS-4. Available from: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2013-39/statement-on-seasonal-influenza-vaccine-2013-2014.html.
58. World Health Organization. Influenza (Seasonal) [cited 2018 Nov 6]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
59. Smit MA, Wang HL, Kim E, et al. Influenza vaccine is protective against laboratory-confirmed influenza in obese children. Pediatr Infect Dis J. 2016;35(4):440−445. doi: https://doi.org/10.1097/INF.0000000000001029
60. Santaularia J, Hou W, Perveen G, et al. Prevalence of influenza vaccination and its association with health conditions and risk factors among Kansas adults in 2013: a cross-sectional study. BMC Public Health. 2016;16:185. doi: https://doi.org/10.1186/s12889-016-2884-5
61. CDC. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521−524.
62. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816−819.
63. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962−1973. doi: https://doi.org/10.1016/S0140-6736(10)62225-8
64. Алексеенко С.А., Багдасарян А.А., Бакулин И.Г., и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. Пособие для врачей-терапевтов / Под ред. О.М. Драпкиной. — М.: Видокс, 2019. — 20 с. [Alekseyenko SA, Bagdasaryan AA, Bakulin IG, et al. Kratkie algoritmy vedeniya patsientov na etape okazaniya pervichnoy mediko-sanitarnoy pomoshchi. Posobie dlya vrachey-terapevtov. Ed. by O.M. Drapkinа. Moscow: Vidoks; 2019. 20 р. (In Russ.)]
65. Salemi S, D’Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010;29(3):270−314. doi: https://doi.org/10.3109/08830185.2010.483028
66. Тарасова А.А., Колбасина Е.В., Лукушкина Е.Ф., и др. Иммуногенность и безопасность трехвалентной иммуноадъювантной субъединичной противогриппозной вакцины у детей с сахарным диабетом 1-го типа: результаты проспективного сравнительного исследования // Вопросы современной педиатрии. — 2016. — Т. 15. — №5. — С. 489–496. [Tarasova АА, Кolbasina ЕV, Lukushkina ЕF, et al. Immunogenicity and safety of a trivalent subunit immunoadjuvant influenza vaccine in children with type 1 diabetes: results of a prospective comparative study. Current Pediatrics. 2016;15(5):489–496. (In Russ.)] doi: https://doi.org/10.15690/vsp.v15i5.1623
Supplementary files
Review
For citations:
Tarasova A.A., Kostinov M.P., Paramonova J.A. Approaches to vaccine prophilaxis of respiratory infections in patients with diabetes mellitus in the modern epidemiological situation. Diabetes mellitus. 2019;22(5):473-480. (In Russ.) https://doi.org/10.14341/DM9820
Views:
2165
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
